Show simple item record

dc.contributor.authorGunn, H
dc.contributor.authorAndrade, J
dc.contributor.authorPaul, L
dc.contributor.authorMiller, L
dc.contributor.authorCreanor, S
dc.contributor.authorGreen, C
dc.contributor.authorMarsden, J
dc.contributor.authorEwings, P
dc.contributor.authorBerrow, M
dc.contributor.authorVickery, J
dc.contributor.authorBarton, A
dc.contributor.authorMarshall, B
dc.contributor.authorZajicek, J
dc.contributor.authorFreeman, JA
dc.date.accessioned2017-08-02T09:49:47Z
dc.date.issued2017-07-27
dc.description.abstractBackground Impaired mobility is a cardinal feature of multiple sclerosis (MS) and is rated by people with MS as their highest priority. By the secondary progressive phase, balance, mobility and physical activity levels are significantly compromised; an estimated 70% of people with secondary progressive MS fall regularly. Our ongoing research has systematically developed ‘Balance Right in MS’ (BRiMS), an innovative, manualised 13-week guided self-management programme tailored to the needs of people with MS, designed to improve safe mobility and minimise falls. Our eventual aim is to assess the clinical and cost effectiveness of BRiMS in people with secondary progressive MS by undertaking an appropriately statistically powered, multi-centre, assessor-blinded definitive, randomised controlled trial. This feasibility study will assess the acceptability of the intervention and test the achievability of running such a definitive trial. Methods/design This is a pragmatic multi-centre feasibility randomised controlled trial with blinded outcome assessment. Sixty ambulant people with secondary progressive MS who self-report two or more falls in the previous 6 months will be randomly allocated (1:1) to either the BRiMS programme plus usual care or to usual care alone. All participants will be assessed at baseline and followed up at 15 weeks and 27 weeks post-randomisation. The outcomes of this feasibility trial include: Feasibility outcomes, including trial recruitment, retention and completion Assessment of the proposed outcome measures for the anticipated definitive trial (including measures of walking, quality of life, falls, balance and activity level) Measures of adherence to the BRiMS programme Data to inform the economic evaluation in a future trial Process evaluation (assessment of treatment fidelity and qualitative evaluation of participant and treating therapist experience) Discussion The BRiMS intervention aims to address a key concern for MS service users and providers. However, there are several uncertainties which need to be addressed prior to progressing to a full-scale trial, including acceptability of the BRiMS intervention and practicality of the trial procedures. This feasibility trial will provide important insights to resolve these uncertainties and will enable a protocol to be finalised for use in the definitive trial.en_GB
dc.description.sponsorshipThis study is funded by the NIHR Health Technology Assessment Programme (14/176/12), United Kingdom. This article presents independent research. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The sponsor of this clinical study is the Plymouth Hospitals NHS Trust, Devon, England, UK.en_GB
dc.identifier.citationVol. 4, article 26en_GB
dc.identifier.doi10.1186/s40814-017-0168-1
dc.identifier.urihttp://hdl.handle.net/10871/28761
dc.language.isoenen_GB
dc.publisherBioMed Centralen_GB
dc.rightsOpen Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.en_GB
dc.subjectSecondary progressive multiple sclerosisen_GB
dc.subjectExerciseen_GB
dc.subjectSelf-managementen_GB
dc.subjectMobilityen_GB
dc.subjectAccidental fallsen_GB
dc.subjectBalanceen_GB
dc.subjectQuality of lifeen_GB
dc.subjectFeasibility randomised controlled trialen_GB
dc.titleBalance Right in Multiple Sclerosis (BRiMS): A guided self-management programme to reduce falls and improve quality of life, balance and mobility in people with secondary progressive multiple sclerosis: a protocol for a feasibility randomised controlled trialen_GB
dc.typeArticleen_GB
dc.date.available2017-08-02T09:49:47Z
dc.descriptionThis is the final version of the article. Available from BioMed Central via the DOI in this record.en_GB
dc.identifier.journalPilot and Feasibility Studiesen_GB
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/


Files in this item

This item appears in the following Collection(s)

Show simple item record

Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Except where otherwise noted, this item's licence is described as Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.